BuscarEventos
Flash is required to view the interactive calendar which can be installed at http://www.adobe.com
Events in detail
2007
EFORT (European Federation of National Associations of Orthopaedics and Traumatology)
EFORT (11th to 15th May 2007)
8th EFORT Congress
Florence, Italy
The European Federation of Orthopaedics and Traumatology (EFORT) promotes the exchange of scientific knowledge and experience. As a Pan-European organisation, EFORT is recognised as representing an outstanding level of orthopaedics.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
May 13th |
Advances in the surgical and clinical management of orthopaedic patients The future potential of oral anticoagulation with rivaroxaban — a once-daily, direct Factor Xa inhibitor. Michael Rud Lassen |
Michelangelo Room, Fortezza da Basso |
12.15–13.45 |
|
|
May 13th |
Guidelines for thromboprophylaxis after major orthopaedic surgery William Geerts |
|
12.15 |
|
|
May 13th |
Minimally invasive hip replacement: the MicroHipTM technique Markus Michel |
|
12.35 |
|
|
May 13th |
Evolution of minimally invasive surgery in total joint arthroplasty: learning curves and pitfalls Louis Kwong |
|
12.50 |
|
|
May 13th |
Anticoagulants for use after major orthopaedic surgery: the story so far … Ander T Cohen |
|
13.05 |
|
|
May 13th |
Anticoagulation with rivaroxaban — a novel, oral, direct Factor Xa inhibitor Bengt Eriksson |
|
13.20 |
|
|
May 13th |
Summary Michael Rud Lassen |
|
13.40 |
|
|
May 13th |
Close
|
|
13.45 |
|
|
May 13th |
The effect of age, gender and weight on the safety and pharmacology of rivaroxaban (BAY 59-7939) – a novel, oral, direct Factor Xa inhibitor Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf |
|
Poster |
|
|
May 13th |
Rivaroxaban – a novel, oral, direct Factor Xa inhibitor – has no clinically relevant interaction with Aspirin or naproxen Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf |
|
Poster |
2008
EFORT (European Federation of National Associations of Orthopaedics and Traumatology)
EFORT (29 May - 1 June 2008)
9th EFORT Congress
Nice, France
The scientific programme includes symposia and instructional lectures delivered by distinguished speakers from across Europe, free papers, posters, workshops, industry symposia and technical exhibits.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
May 30th |
Improving patient outcomes after major orthopaedic surgery Bengt Eriksson and Alexander GG Turpie |
Nice Acropolis |
12:00 - 14:00 |
|
|
May 30th |
Introduction Bengt Eriksson, Sweden |
|
12:15 |
|
|
May 30th |
What's new in total hip and knee replacement? Wolfgang Klauser, Germany |
|
|
|
|
May 30th |
Total hip and knee replacement: an anaesthetist's perspective Nadja Rosencher, France |
|
|
|
|
May 30th |
Reducing the risk of VTE after total hip replacement Ajay Kakkar, UK |
|
|
|
|
May 30th |
Reducing the risk of symptomatic VTE after total knee replacement Michael Rud Lassen, Denmark |
|
|
|
|
May 30th |
Summary Alexander GG Turpie |
|
|
|
|
May 30th |
Close
|
|
14:00 |
AHA (American Heart Association)
AHA (8-12 November 2008 )
American Heart Association's Scientific Sessions 2008
New Orleans, US
The American Heart Association's Scientific Sessions is the premier cardiovascular meeting that offers scientific programming in three broad areas of clinical, basic and population science as well as cross-disciplinary translational science due to the ever-increasing integration of research and patient care.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
Nov 10th |
Plenary Session: Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial Michael C. Gibson |
New Orleans - Congress Center, Hall F |
10:45 - 11 am |
ASH (American Society of Hematology)
ASH (6-9 December 2008 )
50th ASH Annual Meeting and Exposition
San Francisco, US
Held annually in December, the Society's annual meeting provides hematologists from around the world a forum for discussing critical issues in hematology.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
Dec 5th |
CME Symposium - New Perspectives, New Strategies in Venous Thromboembolic Disease Jeffrey Weitz, Charles T. Esmon, Alexander G.G. Turpie and Richard Joel Friedman |
San Francisco Marriott – Yerba Buena Ballroom, Salon 9 |
6 – 10 pm |
|
|
Dec 6th |
Poster Presentation - Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study Louis Kwong |
Moscone Center, Hall A, Poster Board No: I-394 |
5:30 – 7:30 pm |
|
|
Dec 6th |
Poster Presentation - Will Rivaroxaban be Cost-effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients? Louis Kwong |
Moscone Center, Hall A, Poster Board No: I-395 |
5:30 – 7:30 pm |
|
|
Dec 6th |
Poster Presentation - Cost-effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada Philip Wells |
Moscone Center, Hall A, Poster Board No: I-396 |
5:30 – 7:30 pm |
|
|
Dec 6th |
Poster - Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement Alexander Diamantopoulos |
Moscone Center, Hall A, Poster Board No: I-397 |
||
|
Dec 7th |
Paper - Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4 Alexander GG Turpie |
Moscone Center |
5:30 pm |
|
|
Dec 7th |
Paper - A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding Alexander GG Turpie |
Moscone Center |
5:45 pm |
|
|
Dec 7th |
Poster Presentation - A Pooled-analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications Bengt Eriksson |
Moscone Center, Hall A,Poster Board No: II-80 |
6 – 8 pm |
|
|
Dec 8th |
Paper - Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients Bijan Borah |
Moscone Center |
8:15 am |
|
|
Dec 8th |
Paper - Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery Kenneth A. Bauer |
Moscone Center |
2:15 pm |
|
|
Dec 8th |
Paper - Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin– Protein C System Elisabeth Perzborn |
Moscone Center |
2:45 pm |
|
|
Dec 8th |
Poster Presentation - Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates András Gruber |
Moscone Center, Hall A, Poster Board No: III-907 |
5:30 – 7:30 pm |
|
|
Dec 8th |
Poster - Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays Meyer Michel Samama |
Moscone Center, Hall A, Poster Board No: III-110 |
||
|
Dec 8th |
Poster - Improvement of Thrombolysis by Rivaroxaban, An Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis Remi Varin |
Moscone Center, Hall A, Poster Board No: III-113 |
EHA (European Hematology Association)
EHA (12-15 June 2008 )
13th Congress of the European Hematology Association
Copenhagen, Denmark
The Scientific Program Committee of the European Haematology Association and its Advisory Board have taken much effort to generate a timely and stimulating program covering the broad spectrum of benign and malignant hematology.
CHEST (American College of Chest Physicians)
CHEST (25-30 October 2008 )
CHEST 2008
Philadelphia, PA
Recognized around the world as the authority in clinical chest medicine, CHEST 2008 is the one event that can deliver education, experience, expertise.
ICT (International Congress on Thrombosis)
ICT (25–28 June 2008)
20th International Congress on Thrombosis
Athens, Greece
International Thrombosis Congress of MLTD (The Meditteranean League against Thromboembolic Diseases) offers exchange of views and updates on technological advances in the management of Thromboembolic Diseases, as well as new drugs and new therapeutic techniques.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
Jun 27th |
Key Note Lecture Reducing the risk of symptomatic VTE after major orthopaedic surgery: learnings from the RECORD programme Sylvia Haas, Germany |
Room Terpsichore A, Hilton Hotel |
11:00–11:30 |
|
|
Recombinant Factor VIIa reverses the effects of a high dose of rivaroxaban in baboons Andras Gruber, Ulla M Marzec, Ulf Buetehorn, Stephen R Hanson, Elisabeth Perzborn |
Poster |
|||
|
Economic impact of venous thromboprophylaxis with rivaroxaban after major orthopaedic surgery Michael Lees, Nishan Sengupta |
Poster |
|||
|
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and atorvastatin Dagmar Kubitza, Wolfgang Mueck, Michael Becka |
||||
|
Indirect comparison of rivaroxaban regimens vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement Alexander Diamantopoulos, Corinne LeReun, Farhat Rasul, Michael Lees, Maria Kubin |
Poster |
|||
|
FEIBA reverses the effects of a high dose of rivaroxaban in rats Elisabeth Perzborn, Hanna Tinel |
Poster |
|||
|
Relationship between urinary prothrombin fragment 1+2 levels and venous thromboembolic or bleeding events following total hip replacement Lars C Borris, Morten Breindahl, Michael Rud Lassen, Akos Ferenc Pap, Frank Misselwitz |
Poster |
|||
|
Effects of rivaroxaban and fondaparinux on clotting assays Meyer Michel Samama, Léna Le Flem, Céline Guinet, Elisabeth Perzborn, Jean-Luc Martinoli, François Depasse |
Poster |
|||
|
Measuring rivaroxaban pharmacodynamics: prothrombinase-induced clotting time (PiCT®) and Heptest® Meyer Michel Samama, Léna Le Flem, Céline Guinet, Elisabeth Perzborn, François Depasse |
Poster |
|||
|
Concomitant administration of rivaroxaban – an oral, direct Factor Xa inhibitor – with clopidogrel and acetylsalicylic acid enhances antithrombosis in rats Elisabeth Perzborn, Elke Fischer, Uwe Lange |
Poster |
|||
|
Economic burden of venous thromboembolism in the general population and after major orthopaedic surgery – results of a systematic literature review Thomas Steinle, Andras Ruppert, Michael Lees |
Poster |
SSC (International Society on Thrombosis and Haemostasis - Scientific and Standardisation Committee meeting)
SSC (2-5 July 2008)
The 54th Annual Scientific and Standardization Committee Meeting
Vienna, Austria
The purpose of the ISTH's Reach the World Initiative is to foster and support world-wide growth of the field of thrombosis, hemostasis, and vascular biology, particularly in economically developing areas; and to support the next generation of investigators with state-of-the-art knowledge in diseases and disorders of thrombosis, hemostasis and their underlying vascular biology.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
Jul 3rd |
Rivaroxaban: potential clinical impact of simplified oral anticoagulant thromboprophylaxis Exciting results are emerging on a novel, oral, direct Factor Xa inhibitor in development, rivaroxaban. Results of extensive phase III clinical trials – the RECORD programme – that have involved over 12,000 patients worldwide demonstrate the benefits of this oral, easy-to-administer anticoagulant for thromboprophylaxis following total knee or hip replacement and the drug’s potential in other indications. Ajay Kakkar, UK and Kenneth A. Bauer, USA |
Klimt 2, Hilton Vienna |
12:00–13:30 |
|
|
Welcome and introduction Ajay Kakkar, UK and Kenneth A. Bauer, USA |
12:00–12:10 |
|||
|
Clinical benefits of rivaroxaban for thromboprophylaxis after total hip replacement Sylvia Haas, Germany |
12:10–12:35 |
|||
|
Clinical benefits of rivaroxaban for thromboprophylaxis after total knee replacement Walter Ageno, Italy |
12:35–13:00 |
|||
|
Simplifying oral anticoagulation: a clinician’s perspective on rivaroxaban Gregory Lip, UK |
13:00–13:15 |
|||
|
Panel and audience discussion |
13:15–13:30 |
|||
|
Close |
13:30 |
ESC (European Society of Cardiology)
ESC (30 August - 3 September 2008 )
ESC Congress 2008
Munich, Germany
The ESC congress provides a unique forum where medical professionals from all around the world have the opportunity to meet and exchange ideas and information in the field of cardiovascular medicine. The theme of this year's congress: cardiovascular imaging.
Xarelto® Programme
| Fecha | Evento | Relevant material | Location | Time |
|---|---|---|---|---|
|
Sep 1st |
Anticoagulant therapy: new perspectives in cardiovascular medicine The current role of anticoagulants in cardiovascular medicine The need for new oral anticoagulants in clinical practice What can ongoing clinical trials demonstrate? New anticoagulants in developments clinical perspectives C Bode, FWA Verheugt |
Oslo- Zone A1 |
18:30 - 20:00 |
|
|
Welcome and introduction Christoph Bode, Germany |
18:30–18:40 |
|||
|
The current role of anticoagulants in cardiovascular medicine Raffaele de Caterina, Italy |
18:40–18:55 |
|||
|
The need for new oral anticoagulants in clinical practice Elaine Hylek, USA |
18:55–19:10 |
|||
|
What can ongoing clinical trials demonstrate? Jonathan Halperin, USA |
19:10–19:25 |
|||
|
New anticoagulants in development: clinical perspectives Thomas Lüscher, Switzerland |
19:25–19:40 |
|||
|
Panel and audience discussion |
19:40–19:55 |
|||
|
Close Freek Verheugt, The Netherlands |
19:55–20:00 |
|||
|
02. Sep 08 - Abstract Number: 81940, Poster Session 5 (Number 305), Posters Zone B4 The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats Elisabeth Perzborn |
||||
|
03. Sep 08 - Abstract Number: 85236, Poster Session 7 (Number: 307), Posters Zone B4 Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran, but is reduced by the direct factor Xa inhibitor rivaroxaban Elisabeth Perzborn |
||||
|
03. Sep 08 - Abstract Number: 86450, Poster Session 7 (Number 307), Posters Zone B4 A meta-analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding Alexander GG Turpie |
2009
AAOS (American Academy of Orthopaedic Surgeons)
AAOS (25-28 February 2009 )
AAOS 2009 Annual Meeting
Las Vegas, Nevada
The technical exhibits at the AAOS 2009 Annual Meeting, February 25-28, Las Vegas, Nevada, offer you the single, best opportunity to compare products, attend demonstrations and have questions answered by representatives from over 400 companies from around the world.
EFORT (European Federation of National Associations of Orthopaedics and Traumatology)
EFORT (3-6 June 2009 )
10th EFORT Congress
Vienna, Austria
EFORT’s 10th Anniversary Congress in Vienna. The scientific programme includes symposia and instructional lectures delivered by distinguished speakers from across Europe.
EHA (EHA European Hematology Association)
EHA (4-7 June 2009 )
14th Congress of the European Hematology Association
Berlin, Germany
The 14th Congress of the EHA will provide a comprehensive program for clinical and basic hematologists. Important information will be offered in education, scientific, controversial and poster sessions.
ISTH (International Society on Thrombosis and Haemostasis)
ISTH (11-16 Jul 2009 )
55th Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Boston, US
The International Society on Thrombosis and Haemostasis, Inc. is organized and operated exclusively for scientific and educational purposes. Its objectives are to foster and advance science relating to the important medical problems of thrombosis and abnormalities of hemostasis and vascular biology; to provide a forum for discussion of these problems; to encourage research on these problems by scientists of the relevant disciplines; to foster the diffusion and exchange of ideas through scientific meetings and publications; to standardize nomenclature and methods as appropriate and timely.
SICOT (International Society of Orthopaedic Surgery and Traumatology)
SICOT (26–29 Aug 2009 )
Sixth SICOT/SIROT Annual International Conference
Pattaya, Thailand
A major topic, among many others at the Conference, will be the treatment of degenerative conditions affecting the musculoskeletal system. The longer human life span has made this subject an imperative for the orthopaedic surgeon.
ACC (American College of Cardiology - 58th Annual Scientific Session)
ACC (29-31 Mar 2009 )
American College of Cardiology - 58th Annual Scientific Session
Orlando, Florida
The ACC Annual Scientific Session is the largest and foremost cardiovascular meeting, offering attainable, reliable and applicable learning solutions that help CV professionals turn cardiovascular knowledge to practice that saves and improves lives.
ICNC (International Conference of Non-Invasive Cardiovascular Imaging (ESC))
ICNC (10-13 May 2009 )
International Conference of Non-Invasive Cardiovascular Imaging
Barcelona, Spain
The goal of ICNC9, a joint endeavour between the American Society of Nuclear Cardiology (ASNC), the European Association of Nuclear Medicine (EANM) and the ESC Working Group on Nuclear Cardiology and Cardiac Computed Tomography (ESC), is the emphasis on education and continued growth of cardiac imaging within nuclear cardiology.
